Sign inCreate account

Report workspace tools

NCT00193245COMPLETEDanonymous

A Randomized Trial of Oral Topotecan Versus Docetaxel in Second-Line Treatment of Non-Small Cell Lung Cancer

Sponsor

Source record

SCRI Development Innovations, LLC

Phase

Source record

PHASE2

Modality

AI-normalized

small molecule

Target

AI-normalized

Non-Small Cell Lung Cancer

Indication / condition

AI-normalized

Lung Cancer

Intervention

Source record

Topotecan, Docetaxel

Source & freshness

Source record

NCT ID

NCT00193245

Original source

ClinicalTrials.gov

Source last updated

Jun 28, 2010

Ingested at

May 23, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT00193245

Title

A Randomized Trial of Oral Topotecan Versus Docetaxel in Second-Line Treatment of Non-Small Cell Lung Cancer

Sponsor

SCRI Development Innovations, LLC

Status

COMPLETED

Phase

PHASE2

Condition raw

Lung Cancer

Condition normalized

Lung Cancer

Modality raw

Lung Cancer

Modality normalized

small molecule

Target raw

Non-Small Cell Lung Cancer

Target normalized

Non-Small Cell Lung Cancer

Interventions

Topotecan, Docetaxel

Public preview

Source record

This clinical trial evaluated the efficacy and toxicity of oral topotecan compared to intravenous docetaxel in patients with relapsed or progressive non-small cell lung cancer. Conducted by SCRI Development Innovations, LLC, the study involved 80 participants and aimed to determine overall response rates and secondary outcomes such as time to progression and overall survival.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Randomized Trial of Oral Topotecan Versus Docetaxel in Second-Line Treatment of Non-Small Cell Lung Cancer

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT00193245

Status

COMPLETED

Phase

PHASE2

Sponsor

SCRI Development Innovations, LLC

Executive brief

Investment-Ready Snapshot

This clinical trial evaluated the efficacy and toxicity of oral topotecan compared to intravenous docetaxel in patients with relapsed or progressive non-small cell lung cancer. Conducted by SCRI Development Innovations, LLC, the study involved 80 participants and aimed to determine overall response rates and secondary outcomes such as time to progression and overall survival.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedJun 28, 2010
Internal syncJun 05, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT00193245

Indication

Lung Cancer

Modality

small molecule

Target

Non-Small Cell Lung Cancer

Intervention

Topotecan, Docetaxel

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.